April 24th 2024
The FDA has set a Prescription Drug User Fee Act date of August 23, 2024, for dostarlimab in all types of primary advanced endometrial cancer.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Durvalumab Combo Yields Survival Benefit in Advanced Endometrial Cancer
May 29th 2023Data from the phase 3 DUO-E trial indicate that the safety of durvalumab/chemotherapy with or without olaparib/durvalumab or durvalumab monotherapy maintenance in recurrent endometrial cancer was consistent with previous reports of each agent.
Questionnaires Are Comparable in Assessing Lymphedema in Endometrial Cancer
March 27th 2023The lower extremity lymphedema screening questionnaire and gynecological cancer lymphedema questionnaire appear to demonstrate comparable utility in assessing lymphedema in patients with advanced endometrial cancer.
Letrozole/Abemaciclib Demonstrate Promising, Long-Lasting Activity in Recurrent ER+ Endocrine Cancer
November 14th 2022In patients with estrogen receptor–positive recurrent endometrial cancer, letrozole and abemaciclib combination therapy produced an objective response rate of 30% and a median progression-free survival of 9.1 months.
Updated Recommendations from ASTRO for the Adjuvant Treatment of Endometrial Cancer
November 9th 2022In a new set of guidelines by the American Society for Radiation Oncology for the treatment of adjuvant endometrial cancer, experts noted that molecular characterization data should be considered when making recommendations.
VBT Yields Less Urethra Radiation Exposure in Endometrial Cancer vs EBRT in CRC
October 12th 2022Results from a retrospective cohort study indicated that vaginal brachytherapy yielded less radiation exposure to the female urethra in patients with endometrial cancer than external beam radiation therapy for those with colorectal cancer.
Pembrolizumab Yields Lasting Anti-Tumor Activity in MSI-H, dMMR Advanced Endometrial Cancer
September 19th 2022Long-term follow-up from the phase 2 KEYNOTE-158 trial showed enduring anti-tumor activity when pembrolizumab was used to treat patients with microsatellite instability–high/mismatch repair deficient advanced endometrial cancer.